PPARA and cardiovascular disorder: According to the NIH Clinial Trials register, PPAR agonists are now being trialled for cardiovascular disease, hypertension, pre-diabetes, and diabetes, and various PPAR agonists (e.g. pioglitazone, rosiglitazone, fibrates) have been FDA-approved for such therapeutic applications.